ABVX
Abivax S.A.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 29 ▲ Abivax reported positive topline results from Part 2 of the Phase 3…
- Jun 29 ▲ Abivax reported positive topline results from ABTECT Maintenance Par…
- Jun 29 FDA: Abivax Reports Positive ABTECT Maintenance Part 2 Results…
- Jun 30 ▲ 6 funds open new positions (13F)
- Jun 30 Offering: Abivax Announces Launch of Public Offering of American Dep…
- Jul 1 Offering: Correction: Abivax Announces Pricing of Highly Oversubscri…
- Jul 1 ▼ Abivax priced an upsized $800M public offering of 6.4M ADSs at $125…
- Jul 1 Offering: Abivax Announces Pricing of Oversubscribed and Upsized $80…
- Jul 2 ▼ Abivax is raising approximately $759.8 million in net proceeds throu…
- Jul 2 ▼ Abivax SA filed a 6-K on July 2, 2026, disclosing the entry into an…
- Sep 10 Goldman Sachs initiates
- Oct 30 ▲ Short interest falls 43.3% to 4.11M
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 33 added (6 new), 35 trimmed or exited. Largest new: Ra Capital Management, $150.9M, Norges Bank $146.6M.
- AnalystsBULLISH
12 of 14 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.673 → −$0.857 over 90 days. 1 up, 3 down in 30 days.
- Short sellersCOVERING
Short interest −43.3% to 4.11M shares. 4.6 days to cover, ≈4.7% of shares.
- TrendDOWNTREND
11% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 1.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | TRIM | $245.9M |
| CITADEL ADVISORS LLC | DOUBLED | $191.7M |
| RA CAPITAL MANAGEMENT, L.P. | NEW | $150.9M |
| NORGES BANK | NEW | $146.6M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | $140.4M |
| BANK OF AMERICA CORP /DE/ | ADD | $129.5M |
| GOLDMAN SACHS GROUP INC | DOUBLED | $105.6M |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | $80.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analystsPrice is below the lowest target. Median implies +96%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 21, 2026 | Wedbush MAINTAIN | Neutral |
| Oct 20, 2026 | Guggenheim REITERATE | Buy |
| Sep 22, 2026 | Truist Securities MAINTAIN | Buy |
| Sep 22, 2026 | Wedbush MAINTAIN | Neutral |
| Sep 22, 2026 | Barclays MAINTAIN | Overweight |
| Sep 10, 2026 | Goldman Sachs INITIATE | Buy |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.86 | -$1.11–-$0.59 | -12.3% | $676.4K |
| Next Q | -$0.89 | -$1.16–-$0.64 | -15.9% | $686.0K |
| Current FY | -$4.17 | -$4.67–-$3.81 | -16.5% | $4.0M |
| Next FY | -$3.84 | -$4.91–-$2.52 | -14.7% | $71.9M |
Short side
FINRA· Oct 30, 2026SecBot reports
6 filings · 3 press releases · 1 bullish · 2 bearish · 1 mixed · 2 neutral- NEUTRAL INST-CLUSTEROct 30, 2026
Three asset managers increased their ABVX positions in Q3 2026, with Mirae Asset Global…
The cluster is small and lacks insider corroboration, limiting its signal value. Monitor next quarter's 13F filings to see if the buying trend continues or reverses.
- MIXED INST-CLUSTERAug 6, 2026
Four institutional investors doubled their ABVX positions in Q2 2026, led by Pictet Asset…
The doubling of positions by 4 active asset managers signals conviction in Abivax's pipeline, but the 45-day 13F lag means these positions may already be unwound. Monitor for insider buying…
- BEARISH 6-KJul 2, 2026
Abivax SA filed a 6-K on July 2, 2026, disclosing the entry into an underwriting agreement for a…
The $800M capital raise provides Abivax with a substantial cash runway, but the dilutive offering at a ~30% premium to the prior close will likely pressure the stock in the near term as the market…
- BEARISH 424B5Jul 2, 2026
Abivax is raising approximately $759.8 million in net proceeds through a public offering of…
The $800M offering at a 6.2% discount to the prior close ($133.26) creates immediate selling pressure and dilutes existing holders by ~8%. Monitor the stock for continued weakness as the 60-day…
All ABVX filing & press-release reports (9)
- INST-CLUSTER reportOct 30, 2026
- INST-CLUSTER reportAug 6, 2026
- 424B5 reportJul 2, 2026
- 6-K reportJul 2, 2026
- PRESS-RELEASE reportJul 1, 2026
- 6-K reportJun 29, 2026
- PRESS-RELEASE reportJun 29, 2026
- PRESS-RELEASE reportMay 22, 2026
- PRESS-RELEASE reportMar 23, 2026